-
1
-
-
33745915883
-
-
Canadian Cancer Society: Canadian Cancer Statistics 2015. http://www.cancer.ca/en/cancerinformation/cancer-101/canadian-cancer-statisticspublication/? region5on
-
Canadian Cancer Statistics 2015
-
-
-
2
-
-
84918815964
-
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
-
Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
-
(2015)
Int J Cancer
, vol.136
, pp. E359-E386
-
-
Ferlay, J.1
Soerjomataram, I.2
Dikshit, R.3
-
3
-
-
50549121134
-
The distribution of secondary growths in cancer of the breast
-
Paget S: The distribution of secondary growths in cancer of the breast. [reproduced from The Lancet 133:571-573, 1889]
-
(1889)
Reproduced from the Lancet
, vol.133
, pp. 571-573
-
-
Paget, S.1
-
5
-
-
84892813877
-
Does estrogen play a role in response to adjuvant bonetargeted therapies?
-
Russell K, Amir E, Paterson A, et al: Does estrogen play a role in response to adjuvant bonetargeted therapies? J Bone Oncol 2:167-173, 2013
-
(2013)
J Bone Oncol
, vol.2
, pp. 167-173
-
-
Russell, K.1
Amir, E.2
Paterson, A.3
-
6
-
-
84933050150
-
Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting
-
Jacobs C, Amir E, Paterson A, et al: Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. J Bone Oncol 4:54-58, 2015
-
(2015)
J Bone Oncol
, vol.4
, pp. 54-58
-
-
Jacobs, C.1
Amir, E.2
Paterson, A.3
-
7
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 679-691
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
-
8
-
-
66249142333
-
Erratum
-
[Erratum: N Engl J Med 360:2379, 2009]
-
(2009)
N Engl J Med
, vol.360
, pp. 2379
-
-
-
9
-
-
79959565208
-
Adjuvant endocrine therapy plus zoledronic acid in premenopausalwomen with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
-
Gnant M, Mlineritsch B, Stoeger H, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausalwomen with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
-
(2011)
Lancet Oncol
, vol.12
, pp. 631-641
-
-
Gnant, M.1
Mlineritsch, B.2
Stoeger, H.3
-
10
-
-
84925337899
-
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
-
Gnant M, Mlineritsch B, Stoeger H, et al: Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 26:313-320, 2015
-
(2015)
Ann Oncol
, vol.26
, pp. 313-320
-
-
Gnant, M.1
Mlineritsch, B.2
Stoeger, H.3
-
11
-
-
80054035939
-
Breast-cancer adjuvant therapy with zoledronic acid
-
Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
-
(2011)
N Engl J Med
, vol.365
, pp. 1396-1405
-
-
Coleman, R.E.1
Marshall, H.2
Cameron, D.3
-
12
-
-
84905007644
-
Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
-
Coleman R, Cameron D, Dodwell D, et al: Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15:997-1006, 2014
-
(2014)
Lancet Oncol
, vol.15
, pp. 997-1006
-
-
Coleman, R.1
Cameron, D.2
Dodwell, D.3
-
13
-
-
84944177030
-
Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet 386:1353-1361, 2015
-
(2015)
Lancet
, vol.386
, pp. 1353-1361
-
-
-
14
-
-
0031886868
-
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback
-
Browman GP, Newman TE, Mohide EA, et al: Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback. J Clin Oncol 16:1226-1231, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 1226-1231
-
-
Browman, G.P.1
Newman, T.E.2
Mohide, E.A.3
-
15
-
-
0028896975
-
The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation
-
Browman GP, Levine MN, Mohide EA, et al: The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502-512, 1995
-
(1995)
J Clin Oncol
, vol.13
, pp. 502-512
-
-
Browman, G.P.1
Levine, M.N.2
Mohide, E.A.3
-
18
-
-
84959879550
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European panel
-
Hadji P, Coleman RE, Wilson C, et al: Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European panel. Ann Oncol 27:379-390, 2016
-
(2016)
Ann Oncol
, vol.27
, pp. 379-390
-
-
Hadji, P.1
Coleman, R.E.2
Wilson, C.3
-
19
-
-
0036682211
-
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
-
Powles T, Paterson S, Kanis JA, et al: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 3219-3224
-
-
Powles, T.1
Paterson, S.2
Kanis, J.A.3
-
20
-
-
33744828376
-
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
-
Powles T, Paterson A, McCloskey E, et al: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13, 2006
-
(2006)
Breast Cancer Res
, vol.8
, pp. R13
-
-
Powles, T.1
Paterson, A.2
McCloskey, E.3
-
21
-
-
0038103008
-
Extended safety profile of oral clodronate after long-term use in primary breast cancer patients
-
Atula S, Powles T, Paterson A, et al: Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 26:661-671, 2003
-
(2003)
Drug Saf
, vol.26
, pp. 661-671
-
-
Atula, S.1
Powles, T.2
Paterson, A.3
-
22
-
-
75149173381
-
Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer
-
McCloskey E, Paterson A, Kanis J, et al: Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 46:558-565, 2010
-
(2010)
Eur J Cancer
, vol.46
, pp. 558-565
-
-
McCloskey, E.1
Paterson, A.2
Kanis, J.3
-
23
-
-
0032491037
-
Reduction in new metastases in breast cancer with adjuvant clodronate treatment
-
Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998
-
(1998)
N Engl J Med
, vol.339
, pp. 357-363
-
-
Diel, I.J.1
Solomayer, E.F.2
Costa, S.D.3
-
24
-
-
56749165071
-
Adjuvant oral clodronate improves the overall survival of primary breast cancer patientswithmicrometastases to the bone marrow: A long-term follow-up
-
Diel IJ, Jaschke A, Solomayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patientswithmicrometastases to the bone marrow: A long-term follow-up. Ann Oncol 19:2007-2011, 2008
-
(2008)
Ann Oncol
, vol.19
, pp. 2007-2011
-
-
Diel, I.J.1
Jaschke, A.2
Solomayer, E.F.3
-
25
-
-
0035148170
-
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
-
Saarto T, Blomqvist C, Virkkunen P, et al: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 10-17
-
-
Saarto, T.1
Blomqvist, C.2
Virkkunen, P.3
-
26
-
-
9444254706
-
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
-
Saarto T, Vehmanen L, Virkkunen P, et al: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004
-
(2004)
Acta Oncol
, vol.43
, pp. 650-656
-
-
Saarto, T.1
Vehmanen, L.2
Virkkunen, P.3
-
27
-
-
52049093463
-
Tenyear follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer
-
Saarto T, Vehmanen L, Blomqvist C, et al: Tenyear follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26:4289-4295, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 4289-4295
-
-
Saarto, T.1
Vehmanen, L.2
Blomqvist, C.3
-
28
-
-
17644364397
-
Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer
-
Leppä S, Saarto T, Vehmanen L, et al: Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 90:117-125, 2005
-
(2005)
Breast Cancer Res Treat
, vol.90
, pp. 117-125
-
-
Leppä, S.1
Saarto, T.2
Vehmanen, L.3
-
29
-
-
84863109831
-
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial
-
Paterson AH, Anderson SJ, Lembersky BC, et al: Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-742, 2012
-
(2012)
Lancet Oncol
, vol.13
, pp. 734-742
-
-
Paterson, A.H.1
Anderson, S.J.2
Lembersky, B.C.3
-
30
-
-
45149109989
-
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
-
Ejlertsen B, Mouridsen HT, Jensen MB: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol 47:662-671, 2008
-
(2008)
Acta Oncol
, vol.47
, pp. 662-671
-
-
Ejlertsen, B.1
Mouridsen, H.T.2
Jensen, M.B.3
-
31
-
-
45149083364
-
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
-
Kristensen B, Ejlertsen B, Mouridsen HT, et al: Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740-746, 2008
-
(2008)
Acta Oncol
, vol.47
, pp. 740-746
-
-
Kristensen, B.1
Ejlertsen, B.2
Mouridsen, H.T.3
-
32
-
-
84892471140
-
German adjuvant intergroup node-positive study: A phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
-
Von Minckwitz G, Möbus V, Schneeweiss A, et al: German adjuvant intergroup node-positive study: A phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 31:3531-3539, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 3531-3539
-
-
Von Minckwitz, G.1
Möbus, V.2
Schneeweiss, A.3
-
33
-
-
79958182699
-
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer
-
Coleman R, Woodward E, Brown J, et al: Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429-438, 2011
-
(2011)
Breast Cancer Res Treat
, vol.127
, pp. 429-438
-
-
Coleman, R.1
Woodward, E.2
Brown, J.3
-
34
-
-
84890058802
-
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)
-
Rathbone EJ, Brown JE, Marshall HC, et al: Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 31:2685-2691, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 2685-2691
-
-
Rathbone, E.J.1
Brown, J.E.2
Marshall, H.C.3
-
35
-
-
84910665810
-
Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxanebased chemotherapy for primary breast cancer-The phase III NATAN study (GBG 36/ABCSG XX)
-
S5-05
-
Von Minckwitz G, Rezai M, Eidtmann H, et al: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxanebased chemotherapy for primary breast cancer-The phase III NATAN study (GBG 36/ABCSG XX). Cancer Res 73, 2013 (abstr S5-05)
-
(2013)
Cancer Res
, vol.73
-
-
Von Minckwitz, G.1
Rezai, M.2
Eidtmann, H.3
-
37
-
-
84885358543
-
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: Results of a prospective clinical trial
-
Banys M, Solomayer EF, Gebauer G, et al: Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: Results of a prospective clinical trial. BMC Cancer 13:480, 2013
-
(2013)
BMC Cancer
, vol.13
, pp. 480
-
-
Banys, M.1
Solomayer, E.F.2
Gebauer, G.3
-
38
-
-
84864317505
-
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
-
Solomayer EF, Gebauer G, Hirnle P, et al: Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 23:2271-2277, 2012
-
(2012)
Ann Oncol
, vol.23
, pp. 2271-2277
-
-
Solomayer, E.F.1
Gebauer, G.2
Hirnle, P.3
-
39
-
-
77952305169
-
Effect of zoledronic acid on disseminated tumour cells in womenwith locally advanced breast cancer: An open label, randomised, phase 2 trial
-
Aft R, Naughton M, Trinkaus K, et al: Effect of zoledronic acid on disseminated tumour cells in womenwith locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol 11:421-428, 2010
-
(2010)
Lancet Oncol
, vol.11
, pp. 421-428
-
-
Aft, R.1
Naughton, M.2
Trinkaus, K.3
-
40
-
-
84862986485
-
Effect of (neo) adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
-
Aft RL, Naughton M, Trinkaus K, et al: Effect of (neo) adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer 107:7-11, 2012
-
(2012)
Br J Cancer
, vol.107
, pp. 7-11
-
-
Aft, R.L.1
Naughton, M.2
Trinkaus, K.3
-
41
-
-
33947524592
-
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
-
Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 829-836
-
-
Brufsky, A.1
Harker, W.G.2
Beck, J.T.3
-
42
-
-
67649804881
-
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
-
Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
-
(2009)
Clin Breast Cancer
, vol.9
, pp. 77-85
-
-
Brufsky, A.M.1
Bosserman, L.D.2
Caradonna, R.R.3
-
43
-
-
84857370664
-
Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
-
Brufsky AM, Harker WG, Beck JT, et al: Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192-1201, 2012
-
(2012)
Cancer
, vol.118
, pp. 1192-1201
-
-
Brufsky, A.M.1
Harker, W.G.2
Beck, J.T.3
-
44
-
-
77954580167
-
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
-
Eidtmann H, De Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
-
(2010)
Ann Oncol
, vol.21
, pp. 2188-2194
-
-
Eidtmann, H.1
De Boer, R.2
Bundred, N.3
-
45
-
-
84873825231
-
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results
-
Coleman R, De Boer R, Eidtmann H, et al: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24:398-405, 2013
-
(2013)
Ann Oncol
, vol.24
, pp. 398-405
-
-
Coleman, R.1
De Boer, R.2
Eidtmann, H.3
-
46
-
-
84862926420
-
Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial
-
Llombart A, Frassoldati A, Paija O, et al: Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40-48, 2012
-
(2012)
Clin Breast Cancer
, vol.12
, pp. 40-48
-
-
Llombart, A.1
Frassoldati, A.2
Paija, O.3
-
47
-
-
79551534714
-
Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients?
-
270
-
Bryce CJ, Prior J, Sill K, et al: Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients? Proc Am Soc Clin Oncol 21:68a, 2002 (abstr 270)
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
, pp. 68a
-
-
Bryce, C.J.1
Prior, J.2
Sill, K.3
-
48
-
-
58149166777
-
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer
-
Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6336-6342
-
-
Lester, J.E.1
Dodwell, D.2
Purohit, O.P.3
-
49
-
-
84877084313
-
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
-
Lester JE, Dodwell D, Brown JE, et al: Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. J Bone Oncol 1:57-62, 2012
-
(2012)
J Bone Oncol
, vol.1
, pp. 57-62
-
-
Lester, J.E.1
Dodwell, D.2
Brown, J.E.3
-
50
-
-
61449227421
-
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer
-
Hines SL, Mincey BA, Sloan JA, et al: Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047-1053, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 1047-1053
-
-
Hines, S.L.1
Mincey, B.A.2
Sloan, J.A.3
-
51
-
-
77956636088
-
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: Results from the ARBI prospective clinical trial
-
Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al: Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: Results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24, 2010
-
(2010)
Breast Cancer Res
, vol.12
, pp. R24
-
-
Markopoulos, C.1
Tzoracoleftherakis, E.2
Polychronis, A.3
-
52
-
-
77949900992
-
Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial
-
Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 967-975
-
-
Van Poznak, C.1
Hannon, R.A.2
Mackey, J.R.3
-
53
-
-
84878038828
-
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-A randomized biomarker pilot study
-
Winter MC, Wilson C, Syddall SP, et al: Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-A randomized biomarker pilot study. Clin Cancer Res 19:2755-2765, 2013
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2755-2765
-
-
Winter, M.C.1
Wilson, C.2
Syddall, S.P.3
-
54
-
-
84864928163
-
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: The randomized phase 3 HOBOE study
-
Nuzzo F, Gallo C, Lastoria S, et al: Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: The randomized phase 3 HOBOE study. Ann Oncol 23:2027-2033, 2012
-
(2012)
Ann Oncol
, vol.23
, pp. 2027-2033
-
-
Nuzzo, F.1
Gallo, C.2
Lastoria, S.3
-
55
-
-
78651104412
-
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
-
Kim JE, Ahn J-H, Jung KH, et al: Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125:99-106, 2011
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 99-106
-
-
Kim, J.E.1
Ahn, J.-H.2
Jung, K.H.3
-
56
-
-
70349571180
-
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
-
Hines SL, Mincey B, Dentchev T, et al: Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117:603-609, 2009
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 603-609
-
-
Hines, S.L.1
Mincey, B.2
Dentchev, T.3
-
57
-
-
84937518556
-
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
-
Wagner-Johnston ND, Sloan JA, Liu H, et al:5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-2543, 2015
-
(2015)
Cancer
, vol.121
, pp. 2537-2543
-
-
Wagner-Johnston, N.D.1
Sloan, J.A.2
Liu, H.3
-
58
-
-
85021717367
-
Effect of zoledronic acid on bone density of premenopausal breast cancer patients under (neo) adjuvant chemotherapy: The ProBone I study (German)
-
Hadji P, Kauka A, Bauer T, et al: Effect of zoledronic acid on bone density of premenopausal breast cancer patients under (neo) adjuvant chemotherapy: The ProBone I study (German). Senologie - Zeitschrift fü r Mammadiagnostik und -therapie 9:A58, 2012
-
(2012)
Senologie - Zeitschrift Fü R Mammadiagnostik und -therapie
, vol.9
, pp. A58
-
-
Hadji, P.1
Kauka, A.2
Bauer, T.3
-
59
-
-
84897023705
-
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR1 breast cancer: The ProBONE II study
-
Hadji P, Kauka A, Ziller M, et al: Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR1 breast cancer: The ProBONE II study. Osteoporos Int 25:1369-1378, 2014
-
(2014)
Osteoporos Int
, vol.25
, pp. 1369-1378
-
-
Hadji, P.1
Kauka, A.2
Ziller, M.3
-
60
-
-
84896542372
-
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study
-
Hadji P, Kauka A, Ziller M, et al: Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study. Breast Cancer Res Treat 144:343-351, 2014
-
(2014)
Breast Cancer Res Treat
, vol.144
, pp. 343-351
-
-
Hadji, P.1
Kauka, A.2
Ziller, M.3
-
61
-
-
82955165853
-
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial
-
Safra T, Bernstein-Molho R, Greenberg J, et al: The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial. Oncology 81:298-305, 2011
-
(2011)
Oncology
, vol.81
, pp. 298-305
-
-
Safra, T.1
Bernstein-Molho, R.2
Greenberg, J.3
-
62
-
-
84922349261
-
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery
-
558
-
Gralow J, Barlow WE, Paterson A H G, et al: SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol 32, 2014 (abstr 558)
-
(2014)
J Clin Oncol
, pp. 32
-
-
Gralow, J.1
Barlow, W.E.2
Paterson, A.H.G.3
-
63
-
-
84945570878
-
Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRGOncology Study S0307
-
503
-
Gralow J, Barlow WE, Paterson A H G, et al: Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRGOncology Study S0307. J Clin Oncol 33, 2015 (abstr 503)
-
(2015)
J Clin Oncol
, pp. 33
-
-
Gralow, J.1
Barlow, W.E.2
Paterson, A.H.G.3
-
64
-
-
84938751180
-
Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial
-
Gnant M, Pfeiler G, Dubsky PC, et al: Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433-443, 2015
-
(2015)
Lancet
, vol.386
, pp. 433-443
-
-
Gnant, M.1
Pfeiler, G.2
Dubsky, P.C.3
-
65
-
-
84984825009
-
The impact of adjuvant denosumab on disease-free survival: Results from 3, 425 postmenopausal patients of the ABCSG-18 trial
-
S2-02
-
Gnant M, Pfeiler G, Dubsky PC, et al: The impact of adjuvant denosumab on disease-free survival: Results from 3, 425 postmenopausal patients of the ABCSG-18 trial. Cancer Res 76, 2016 (abstr S2-02)
-
(2016)
Cancer Res
, pp. 76
-
-
Gnant, M.1
Pfeiler, G.2
Dubsky, P.C.3
-
66
-
-
85021713426
-
-
Gnant M: The impact of adjuvant denosumab on disease-free survival: Results from 3, 425 postmenopausal patients of the ABCSG-18 trial. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
-
The Impact of Adjuvant Denosumab on Disease-free Survival: Results from 3, 425 Postmenopausal Patients of the ABCSG-18 Trial. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
-
-
Gnant, M.1
-
67
-
-
0033870883
-
Adjuvant clodronate therapy in patients with locally advanced breast cancer-Long term results of a double blind randomized trial
-
Mardiak J, Bohunickćy L, Chovanec J, et al: Adjuvant clodronate therapy in patients with locally advanced breast cancer-Long term results of a double blind randomized trial. Neoplasma 47:177-180, 2000
-
(2000)
Neoplasma
, vol.47
, pp. 177-180
-
-
Mardiak, J.1
Bohunickćy, L.2
Chovanec, J.3
-
68
-
-
84955488881
-
Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)
-
Hasegawa Y, Tanino H, Horiguchi J, et al: Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study). PLoS One 10:e0143643, 2015
-
(2015)
PLoS One
, vol.10
, pp. e0143643
-
-
Hasegawa, Y.1
Tanino, H.2
Horiguchi, J.3
-
69
-
-
85021710223
-
Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)
-
PD3-7
-
Miura D, Hasegawa Y, Horiguchi J, et al: Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study). Cancer Res 73, 2013 (abstr PD3-7)
-
(2013)
Cancer Res
, pp. 73
-
-
Miura, D.1
Hasegawa, Y.2
Horiguchi, J.3
-
70
-
-
85021714934
-
A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
-
PD07-05
-
Hasegawa Y, Kohno N, Horiguchi J, et al: A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. Cancer Res 72:2012 (abstr PD07-05)
-
Cancer Res
, vol.72
, pp. 2012
-
-
Hasegawa, Y.1
Kohno, N.2
Horiguchi, J.3
-
71
-
-
84883208612
-
A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
-
1029
-
Horiguchi J, Hasegawa Y, Miura D, et al: A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol 31, 2013 (abstr 1029)
-
(2013)
J Clin Oncol
, pp. 31
-
-
Horiguchi, J.1
Hasegawa, Y.2
Miura, D.3
-
72
-
-
85021750140
-
Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients
-
P5-15-04
-
El-Ibrashi MM, El-Sadda WM, Abdel-Halim II, et al: Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients. Cancer Res 76, 2016 (abstr P5-15-04)
-
(2016)
Cancer Res
, pp. 76
-
-
El-Ibrashi, M.M.1
El-Sadda, W.M.2
Abdel-Halim, I.I.3
-
73
-
-
84863716562
-
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
-
Takahashi S, Iwase T, Kohno N, et al: Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685-693, 2012
-
(2012)
Breast Cancer Res Treat
, vol.133
, pp. 685-693
-
-
Takahashi, S.1
Iwase, T.2
Kohno, N.3
-
74
-
-
85021731406
-
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results
-
e20510
-
Takahashi S, Iwase T, Kohno N, et al: Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results. J Clin Oncol 31, 2013 (abstr e20510)
-
(2013)
J Clin Oncol
, pp. 31
-
-
Takahashi, S.1
Iwase, T.2
Kohno, N.3
-
75
-
-
85021701005
-
Assessment of bisphosphonates use as adjuvant therapy in breast cancer
-
304p
-
Abu-Taleb FM, El-Zawahry HM, Zekri ZK, et al: Assessment of bisphosphonates use as adjuvant therapy in breast cancer. Ann Oncol 25: iv101-iv102, 2014 (abstr 304p)
-
(2014)
Ann Oncol
, vol.25
, pp. iv101-iv102
-
-
Abu-Taleb, F.M.1
El-Zawahry, H.M.2
Zekri, Z.K.3
-
76
-
-
85032590769
-
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebocontrolled, randomized, double-blind, phase 3 clinical trial
-
OT2-6-02
-
Goss PE, Barrios CH, Chan A, et al: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebocontrolled, randomized, double-blind, phase 3 clinical trial. Cancer Res 73, 2013 (abstr OT2-6-02)
-
(2013)
Cancer Res
, pp. 73
-
-
Goss, P.E.1
Barrios, C.H.2
Chan, A.3
-
78
-
-
0027478423
-
Meta-analysis of the literature or of individual patient data: Is there a difference?
-
Stewart LA, Parmar MK: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
-
(1993)
Lancet
, vol.341
, pp. 418-422
-
-
Stewart, L.A.1
Parmar, M.K.2
-
79
-
-
85021746677
-
-
Netherlands Cancer Institute: Scientific annual report 2014. http://www.nki.nl/media/1388517/scientific %20annual%20report%202014%20LR.pdf
-
Scientific Annual Report 2014
-
-
-
80
-
-
84873393857
-
Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer
-
Andergassen U, Kasprowicz NS, Hepp P, et al: Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer. Geburtshilfe Frauenheilkd 73:63-69, 2013
-
(2013)
Geburtshilfe Frauenheilkd
, vol.73
, pp. 63-69
-
-
Andergassen, U.1
Kasprowicz, N.S.2
Hepp, P.3
-
81
-
-
85021772716
-
Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study
-
P4-11-21
-
Rack B, Fasching PA, Haberle L, et al: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study. Cancer Res 75, 2015 (abstr P4-11-21)
-
(2015)
Cancer Res
, pp. 75
-
-
Rack, B.1
Fasching, P.A.2
Haberle, L.3
-
82
-
-
84865016897
-
Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review
-
Varun BR, Sivakumar TT, Nair BJ, et al: Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review. J Oral Maxillofac Pathol 16:210-214, 2012
-
(2012)
J Oral Maxillofac Pathol
, vol.16
, pp. 210-214
-
-
Varun, B.R.1
Sivakumar, T.T.2
Nair, B.J.3
-
83
-
-
84919691137
-
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
-
Inderjeeth CA, Glendenning P, Ratnagobal S, et al: Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health 7:7-17, 2014
-
(2014)
Int J Womens Health
, vol.7
, pp. 7-17
-
-
Inderjeeth, C.A.1
Glendenning, P.2
Ratnagobal, S.3
-
84
-
-
80054862345
-
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials
-
Lee YH, Song GG: Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340-347, 2011
-
(2011)
Korean J Intern Med
, vol.26
, pp. 340-347
-
-
Lee, Y.H.1
Song, G.G.2
-
85
-
-
5444243800
-
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
-
Conte P, Guarneri V: Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9:28-37, 2004(suppl 4)
-
(2004)
Oncologist
, vol.9
, pp. 28-37
-
-
Conte, P.1
Guarneri, V.2
-
86
-
-
85021760639
-
Clodronate
-
August
-
Cancer Care Ontario: Clodronate. Drug monograph. CCO formulary, August 2015. https://www.cancercare.on. ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx?itemId593927
-
(2015)
Drug Monograph. CCO Formulary
-
-
-
87
-
-
84875718985
-
The incidence of acute anterior uveitis after intravenous zoledronate
-
Patel DV, Horne A, House M, et al: The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 120:773-776, 2013
-
(2013)
Ophthalmology
, vol.120
, pp. 773-776
-
-
Patel, D.V.1
Horne, A.2
House, M.3
-
88
-
-
84861148411
-
Inflammatory ocular adverse events with the use of oral bisphosphonates: A retrospective cohort study
-
Etminan M, Forooghian F, Maberley D: Inflammatory ocular adverse events with the use of oral bisphosphonates: A retrospective cohort study. CMAJ 184:E431-E434, 2012
-
(2012)
CMAJ
, vol.184
, pp. E431-E434
-
-
Etminan, M.1
Forooghian, F.2
Maberley, D.3
-
89
-
-
33646863929
-
Management of the adverse effects associated with intravenous bisphosphonates
-
Tanvetyanon T, Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897-907, 2006
-
(2006)
Ann Oncol
, vol.17
, pp. 897-907
-
-
Tanvetyanon, T.1
Stiff, P.J.2
-
90
-
-
84861670957
-
Antiresorptive treatment options and bone health in cancer patients-Safety profiles and clinical considerations
-
Hadji P, Aapro M, Costa L, et al: Antiresorptive treatment options and bone health in cancer patients-Safety profiles and clinical considerations. Cancer Treat Rev 38:815-824, 2012
-
(2012)
Cancer Treat Rev
, vol.38
, pp. 815-824
-
-
Hadji, P.1
Aapro, M.2
Costa, L.3
-
91
-
-
78649680817
-
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary
-
Papaioannou A, Morin S, Cheung AM, et al:2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 182:1864-1873, 2010
-
(2010)
CMAJ
, vol.182
, pp. 1864-1873
-
-
Papaioannou, A.1
Morin, S.2
Cheung, A.M.3
-
92
-
-
85021738111
-
Osteoporosis: Clinical guideline for prevention and treatment
-
Updated January
-
National Osteoporosis Guideline Group: Osteoporosis: Clinical guideline for prevention and treatment. Executive summary. Updated January 2016. www.shef.ac.uk/NOGG/NOGG-Executive-Summary.pdf
-
(2016)
Executive Summary
-
-
-
93
-
-
84919418591
-
Clinician's guide to prevention and treatment of osteoporosis
-
Cosman F, De Beur SJ, LeBoff MS, et al: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359-2381, 2014
-
(2014)
Osteoporos Int
, vol.25
, pp. 2359-2381
-
-
Cosman, F.1
De Beur, S.J.2
LeBoff, M.S.3
-
94
-
-
85021699321
-
Erratum
-
[Erratum: Osteoporos Int 26:2045-2047, 2015]
-
(2015)
Osteoporos Int
, vol.26
, pp. 2045-2047
-
-
-
95
-
-
84969760966
-
Postmenopausal osteoporosis
-
Black DM, Rosen CJ: Postmenopausal osteoporosis. N Engl J Med 374:254-262, 2016
-
(2016)
N Engl J Med
, vol.374
, pp. 254-262
-
-
Black, D.M.1
Rosen, C.J.2
-
97
-
-
84976389243
-
Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of Cancer Care Ontario guideline recommendations
-
Henry NL, Somerfield MR, Abramson VG, et al: Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of Cancer Care Ontario guideline recommendations. J Clin Oncol 34:2303-2311, 2016
-
(2016)
J Clin Oncol
, vol.34
, pp. 2303-2311
-
-
Henry, N.L.1
Somerfield, M.R.2
Abramson, V.G.3
-
98
-
-
25444477545
-
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
-
Cramer JA, Amonkar MM, Hebborn A, et al: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. CurrMed ResOpin 21:1453-1460, 2005
-
(2005)
CurrMed ResOpin
, vol.21
, pp. 1453-1460
-
-
Cramer, J.A.1
Amonkar, M.M.2
Hebborn, A.3
-
99
-
-
79551568488
-
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study
-
Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 5132-5139
-
-
Stopeck, A.T.1
Lipton, A.2
Body, J.J.3
-
100
-
-
84867582660
-
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
-
Lipton A, Fizazi K, Stopeck AT, et al: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092, 2012
-
(2012)
Eur J Cancer
, vol.48
, pp. 3082-3092
-
-
Lipton, A.1
Fizazi, K.2
Stopeck, A.T.3
-
101
-
-
84882759793
-
Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies
-
Qi WX, Lin F, He AN, et al: Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29:1067-1073, 2013
-
(2013)
Curr Med Res Opin
, vol.29
, pp. 1067-1073
-
-
Qi, W.X.1
Lin, F.2
He, A.N.3
-
103
-
-
84957609430
-
Managing osteoporosis in patients on longterm bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research
-
Adler RA, El-Hajj Fuleihan G, Bauer DC, et al: Managing osteoporosis in patients on longterm bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16-35, 2016
-
(2016)
J Bone Miner Res
, vol.31
, pp. 16-35
-
-
Adler, R.A.1
El-Hajj Fuleihan, G.2
Bauer, D.C.3
-
104
-
-
33750049947
-
Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients
-
Braverman SA, Sawhney H, Tendler A, et al: Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients. Therapy 3:609-612, 2006
-
(2006)
Therapy
, vol.3
, pp. 609-612
-
-
Braverman, S.A.1
Sawhney, H.2
Tendler, A.3
-
105
-
-
0017190910
-
Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
-
Groom GV, Griffiths K: Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421-428, 1976
-
(1976)
J Endocrinol
, vol.70
, pp. 421-428
-
-
Groom, G.V.1
Griffiths, K.2
-
106
-
-
84919934170
-
Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus
-
Khan AA, Morrison A, Hanley DA, et al: Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 30:3-23, 2015
-
(2015)
J Bone Miner Res
, vol.30
, pp. 3-23
-
-
Khan, A.A.1
Morrison, A.2
Hanley, D.A.3
-
107
-
-
84909619222
-
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update
-
Ruggiero SL, Dodson TB, Fantasia J, et al: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938-1956, 2014
-
(2014)
J Oral Maxillofac Surg
, vol.72
, pp. 1938-1956
-
-
Ruggiero, S.L.1
Dodson, T.B.2
Fantasia, J.3
-
108
-
-
82055162846
-
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs
-
Hellstein JW, Adler RA, Edwards B, et al: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243-1251, 2011
-
(2011)
J Am Dent Assoc
, vol.142
, pp. 1243-1251
-
-
Hellstein, J.W.1
Adler, R.A.2
Edwards, B.3
-
110
-
-
85021762831
-
-
Centers for Disease Control and Prevention: Division of Oral Health: Oral health for adults. http://www.cdc.gov/oralhealth/publications/factsheets/adult-oral-health/adults.htm
-
Division of Oral Health: Oral Health for Adults
-
-
-
115
-
-
85021727302
-
-
April
-
Cancer Care Onatrio: ZOLE regimen. Zoledronic acid. CCO formulary, April 2016. https://www.cancercare.on. ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx?itemId5325962
-
(2016)
ZOLE Regimen. Zoledronic Acid. CCO Formulary
-
-
-
116
-
-
30744458738
-
-
Novartis Pharmaceuticals Corporation: Zometa (zoledronic acid). www.accessdata.fda.gov/drugsatfda-docs/label/2016/021223s034lbl.pdf
-
Zometa (zoledronic Acid)
-
-
-
117
-
-
85021771495
-
-
Apotex Corp: Zoledronic acid. http://medlibrary.org/lib/rx/meds/zoledronic-acid-15
-
Zoledronic Acid
-
-
-
118
-
-
84922155743
-
Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: What are the risks?
-
Clark EM, Durup D: Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: What are the risks? Ther Adv Musculoskelet Dis 7:11-16, 2015
-
(2015)
Ther Adv Musculoskelet Dis
, vol.7
, pp. 11-16
-
-
Clark, E.M.1
Durup, D.2
-
119
-
-
0037456760
-
Bisphosphonates and ocular inflammation
-
Fraunfelder FW, Fraunfelder FT: Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188, 2003
-
(2003)
N Engl J Med
, vol.348
, pp. 1187-1188
-
-
Fraunfelder, F.W.1
Fraunfelder, F.T.2
-
122
-
-
84938740077
-
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
-
Body J-J, Bone HG, De Boer RH, et al: Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812-1821, 2015
-
(2015)
Eur J Cancer
, vol.51
, pp. 1812-1821
-
-
Body, J.-J.1
Bone, H.G.2
De Boer, R.H.3
-
123
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
-
Cummings SR, San Martin J, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765, 2009
-
(2009)
N Engl J Med
, vol.361
, pp. 756-765
-
-
Cummings, S.R.1
San Martin, J.2
McClung, M.R.3
-
125
-
-
84873979722
-
Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database
-
Pazianas M, Clark EM, Eiken PA, et al: Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database. J Bone Miner Res 28:455-463, 2013
-
(2013)
J Bone Miner Res
, vol.28
, pp. 455-463
-
-
Pazianas, M.1
Clark, E.M.2
Eiken, P.A.3
-
127
-
-
34848887818
-
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid
-
Brown JE, Ellis SP, Lester JE, et al: Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406-5410, 2007
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5406-5410
-
-
Brown, J.E.1
Ellis, S.P.2
Lester, J.E.3
-
128
-
-
85021763391
-
Investigating denosumab as add-on neoadjuvant treatment for hormone receptornegative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX)
-
TPS635
-
Kummel S, Von Minckwitz G, Nekljudova V, et al: Investigating denosumab as add-on neoadjuvant treatment for hormone receptornegative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). J Clin Oncol 34:2016 (abstr TPS635)
-
J Clin Oncol
, vol.34
, pp. 2016
-
-
Kummel, S.1
Von Minckwitz, G.2
Nekljudova, V.3
|